Lead Product(s) : Regenerative Epidermal Cell
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The RECELL® System technology platform, approved by the FDA for the treatment of acute thermal burns in both adults and children, harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ cells.
Product Name : RECELL
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 11, 2022
Lead Product(s) : Regenerative Epidermal Cell
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dehydrated Human Amnion Chorion Membrane
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Undisclosed
Sponsor : U.S. Army Medical Research and Development
Deal Size : $4.6 million
Deal Type : Funding
Details : The award will be used to advance the clinical understanding of PURION® processed Dehydrated Human Amnion Chorion Membrane, specifically in treating acute injuries and preventing initially partial-thickness burns from deteriorating to full-thickness bur...
Product Name : DHACM
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 31, 2022
Lead Product(s) : Dehydrated Human Amnion Chorion Membrane
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Sponsor : U.S. Army Medical Research and Development
Deal Size : $4.6 million
Deal Type : Funding
Lead Product(s) : Pathogen Reduced Lyophilized Cryoprecipitate
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Undisclosed
Sponsor : U.S. Department of Defense
Deal Size : $9.1 million
Deal Type : Funding
Details : Cerus’ LyoCryo, a pathogen reduced, lyophilized cryoprecipitate, is being designed for shelf stability, rapid availability, and portability, enabling administration to patients in remote environments with the aim of increasing survival from traumatic i...
Product Name : LyoCryo
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
February 11, 2022
Lead Product(s) : Pathogen Reduced Lyophilized Cryoprecipitate
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Sponsor : U.S. Department of Defense
Deal Size : $9.1 million
Deal Type : Funding
Lead Product(s) : Adenosine Analog
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Undisclosed
Sponsor : Adial Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the Agreement, Purnovate will supply lead adenosine compounds and research team will be responsible for evaluating these compounds for efficacy and determination of the ideal formulations for maximum absorption with the goal of initiating future cl...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 28, 2021
Lead Product(s) : Adenosine Analog
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Sponsor : Adial Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Entolimod
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Statera Biopharma Announces FDA Lifts Clinical Hold on Entolimod
Details : Statera is establishing a development program in Oncology and Hematology based on the potential that toll-like receptor 5 agonists, such as Entolimod, have shown in the treatment of neutropenia and anemia in cancer patients.
Product Name : CBLB502
Product Type : Peptide
Upfront Cash : Inapplicable
January 12, 2021
Lead Product(s) : Entolimod
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Undisclosed
Sponsor : Catalys Pacific
Deal Size : $15.0 million
Deal Type : Series A Financing
Details : The new company is focused on the development of first-in-class therapies for the treatment of inflammatory disorders with an initial target indication of the prevention of postoperative delirium.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 16, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Sponsor : Catalys Pacific
Deal Size : $15.0 million
Deal Type : Series A Financing
Lead Product(s) : Acetylcysteine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Undisclosed
Sponsor : ATAI Life Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partners will develop a short-term treatment which includes intranasal delivery of low doses of N-acetylcysteine for mild Traumatic Brain Injury (mTBI) or concussion.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 01, 2020
Lead Product(s) : Acetylcysteine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Sponsor : ATAI Life Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Dantrolene
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Undisclosed
Sponsor : Eagle Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, NorthShore University HealthSystem will study Eagle’s RYANODEX® (dantrolene sodium) for traumatic brain injury (TBI) in animal models.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 01, 2020
Lead Product(s) : Dantrolene
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Sponsor : Eagle Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Buntanetap
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Annovis Bio filed a patent application with the USPTO concerning a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans and in animals via by ANVS401 or related ...
Product Name : ANVS401
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 27, 2020
Lead Product(s) : Buntanetap
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Autologous Regenerative Epidermal Cell
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This study seeks to demonstrate that treatment with the RECELL System of partial-thickness burn injuries within 72-hours can safely increase the healing at day 10.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 03, 2020
Lead Product(s) : Autologous Regenerative Epidermal Cell
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable